Skip to main content
. 2021 May 28;9(5):e002432. doi: 10.1136/jitc-2021-002432

Figure 6.

Figure 6

In situ injection of iPSC-DCs with local RT increases antigen-specific CD8+ T cell infiltrates in the tumor. (A) Experimental set-up. (B) Representative flow cytometric plots showing OT-I T cells (CD90.1+ CD8+) in CD45+ cells in tumors. Data panels show numbers (/g) (tumor) of OT-I T cells (n=3). (C) Representative flow cytometric plots showing expression of Slamf6 and TIM3 in OT-I (CD90.1+) and endogenous (CD90.2+) CD8+ TILs. Numbers denote per cent Slamf6+ TIM3− T cells. (D) Tumor growth curves (mean) (left) and tumor weight (right) of B16-OVA tumor-bearing mice in different treatment as indicated. (n=5). (E) Numbers (/g) (tumor) of OT-I T cells (n=5). Each dot represents biologically independent mice (B, D–F). NS not significant, *p<0.05, **p<0.01, ***p<0.001, one-way ANOVA with Tukey’s multiple comparisons (B, D, E) and two-tailed paired (C) and unpaired (F) t-test. Mean±SEM. ANOVA, analysis of variance; BM-DCs, bone marrow-derived dendritic cells; iPSC-DC, induced pluripotent stem cell-derived dendritic cells; i.t., intratumorally; OVA, ovalbumin; RT, radiotherapy; TILs, tumor-infiltrating lymphocytes; TIM3, T cell immunoglobulin and mucin domain-containing protein 3.